Page 157 - Read Online

Spiliopoulou et al. Cancer Drug Resist 2024;7:2 https://dx.doi.org/10.20517/cdr.2023.46 Page 25

negative advanced-stage breast cancer patients. Clin Cancer Res 2007;13:2714-21. DOI
192. Gutierrez L, Jang M, Zhang T, Akhtari M, Alachkar H. Midostaurin reduces regulatory T cells markers in acute myeloid leukemia.
Sci Rep 2018;8:17544. DOI PubMed PMC
193. Wilson KR, Villadangos JA, Mintern JD. Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy. Immunol Cell
Biol 2021;99:962-71. DOI PubMed
194. Redin E, Garmendia I, Lozano T, et al. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in
NSCLC models by inhibiting Treg cell conversion and proliferation. J Immunother Cancer 2021;9:e001496. DOI PubMed PMC
195. Pantziarka P, Vandeborne L, Bouche G. A database of drug repurposing clinical trials in oncology. Front Pharmacol
2021;12:790952. DOI PubMed PMC
196. Stransky N, Ruth P, Schwab M, Löffler MW. Can any drug be repurposed for cancer treatment? Cancers 2021;13:6236. DOI
PubMed PMC